Report of a collaborative study to establish the first Indian Pharmacopoeia reference standard for teriparatide

IF 1.5 4区 生物学 Q4 BIOCHEMICAL RESEARCH METHODS Biologicals Pub Date : 2024-03-12 DOI:10.1016/j.biologicals.2024.101755
Gaurav Pratap Singh Jadaun , M. Kalaivani , Mukesh Kumar , Gyanendra Nath Singh , Rajeev Singh Raghuvanshi , Parveen Jain , Participants of the Study
{"title":"Report of a collaborative study to establish the first Indian Pharmacopoeia reference standard for teriparatide","authors":"Gaurav Pratap Singh Jadaun ,&nbsp;M. Kalaivani ,&nbsp;Mukesh Kumar ,&nbsp;Gyanendra Nath Singh ,&nbsp;Rajeev Singh Raghuvanshi ,&nbsp;Parveen Jain ,&nbsp;Participants of the Study","doi":"10.1016/j.biologicals.2024.101755","DOIUrl":null,"url":null,"abstract":"<div><p>A collaborative study was conducted to establish the first Indian Pharmacopoeia Reference Standard (IPRS) for teriparatide to be used in quality control testing of marketed products in compliance with the Indian Pharmacopoeia (IP) monograph. The study objective was to evaluate the candidate standard in terms of the WHO International Standard (IS) to assign its content in mg per vial terms. This study involved four laboratories from India and the candidate standard was calibrated against the WHO IS by each participant laboratory using high-performance liquid chromatography (HPLC) assay method per IP monograph. Direct calibration of the candidate standard resulted in an assigned content of 1.02 mg per vial. Based on the study results the candidate standard was judged suitable to serve as the first IPRS for teriparatide for identification and assay by HPLC.</p></div>","PeriodicalId":55369,"journal":{"name":"Biologicals","volume":"86 ","pages":"Article 101755"},"PeriodicalIF":1.5000,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologicals","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1045105624000125","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

A collaborative study was conducted to establish the first Indian Pharmacopoeia Reference Standard (IPRS) for teriparatide to be used in quality control testing of marketed products in compliance with the Indian Pharmacopoeia (IP) monograph. The study objective was to evaluate the candidate standard in terms of the WHO International Standard (IS) to assign its content in mg per vial terms. This study involved four laboratories from India and the candidate standard was calibrated against the WHO IS by each participant laboratory using high-performance liquid chromatography (HPLC) assay method per IP monograph. Direct calibration of the candidate standard resulted in an assigned content of 1.02 mg per vial. Based on the study results the candidate standard was judged suitable to serve as the first IPRS for teriparatide for identification and assay by HPLC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
建立首个印度药典特立帕肽参考标准的合作研究报告
一项合作研究旨在建立首个特立帕肽印度药典标准物质(IPRS),用于对符合印度药典(IP)专著的上市产品进行质量控制检测。研究的目的是根据世界卫生组织国际标准(IS)对候选标准进行评估,以确定其含量(每瓶毫克)。这项研究涉及印度的四个实验室,每个参与研究的实验室都根据 IP 专著,采用高效液相色谱 (HPLC) 分析方法,对照世界卫生组织国际标准对候选标准进行了校准。候选标准物质的直接校准结果是每小瓶的指定含量为 1.02 毫克。根据研究结果,候选标准品被认为适合作为特立帕肽的首个 IPRS,通过 HPLC 进行鉴定和检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Biologicals
Biologicals 生物-生化研究方法
CiteScore
3.70
自引率
0.00%
发文量
39
审稿时长
48 days
期刊介绍: Biologicals provides a modern and multidisciplinary international forum for news, debate, and original research on all aspects of biologicals used in human and veterinary medicine. The journal publishes original papers, reviews, and letters relevant to the development, production, quality control, and standardization of biological derived from both novel and established biotechnologies. Special issues are produced to reflect topics of particular international interest and concern.Three types of papers are welcome: original research reports, short papers, and review articles. The journal will also publish comments and letters to the editor, book reviews, meeting reports and information on regulatory issues.
期刊最新文献
Optimization of a U937 cell-based reporter system to assess ADCC activity of ustekinumab versus trastuzumab. Preparation of poloxamer-based CPV virus-like particle vaccine and its immunological evaluation in mice. Oral immunization with engineered probiotics expressing tcdB protects mice against Clostridioides difficile infection. Corrigendum to "Preparedness and response to emerging veterinary disease outbreaks - A meeting report" [Biologicals 93 (February 2026) 101873]. Aims and Scope/Editorial Board/Publishing Details
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1